The promise and peril of surrogate end points in cancer research

Nature Reviews. Cancer
Arthur Schatzkin, M H Gail

Abstract

Both experimental and observational studies of cancer need to have an end point. Traditionally, in aetiological and prevention studies, that end point has been the incidence of cancer itself, whereas in therapeutic trials, the end point is usually time to cancer recurrence or death. But cancer takes a long time to develop in an individual and is rare in the population. Therefore, aetiological studies and prevention trials must be large and lengthy to be meaningful. Similarly, many therapeutic trials require a long follow-up of large numbers of patients. Surrogate end points--markers of preclinical cancer or of imminent recurrence--are therefore an attractive alternative. But how can we be sure that a study with a surrogate outcome gives us the right answer about the true end point?

References

Mar 18, 1992·Journal of the National Cancer Institute·M H Schiffman
Jan 30, 1992·Statistics in Medicine·L S FreedmanA Schatzkin
Jun 1, 1990·Cell·E R Fearon, B Vogelstein
Mar 1, 1989·American Journal of Epidemiology·A F SaftlasM Szklo
Sep 6, 1995·Journal of the National Cancer Institute·J A BaronR Rothstein
Feb 1, 1995·Journal of the National Cancer Institute·P G TonioloB S Pasternack
Jul 20, 1994·Journal of the National Cancer Institute·A SchatzkinE Lanza
Jun 16, 1993·Journal of the National Cancer Institute·M H SchiffmanS Wacholder
May 5, 1993·Journal of the National Cancer Institute·M E ReichmanP R Taylor
Jan 1, 1995·Journal of Cellular Biochemistry. Supplement·B Y Karlan
Oct 1, 1996·Annals of Internal Medicine·T R Fleming, D L DeMets
Feb 1, 1997·The Journal of Infectious Diseases·V De GruttolaR Coombs
Sep 26, 1997·Statistics in Medicine·M J Daniels, M D Hughes
Sep 10, 1998·Journal of the National Cancer Institute·S E HankinsonF E Speizer
Jan 14, 1999·The New England Journal of Medicine·J A BaronE R Greenberg
Jan 23, 1999·Nature Genetics·P O Brown, D Botstein
Feb 19, 1999·Journal of Epidemiology and Community Health·C Poole, K J Rothman
Aug 27, 1999·JAMA : the Journal of the American Medical Association·R Temple
May 4, 2000·Journal of the National Cancer Institute·H zur Hausen
Mar 7, 2001·Lancet·F Balkwill, A Mantovani
Sep 26, 2002·Epidemiology·K J Rothman
Aug 23, 2003·Biostatistics·M H GailR J Carroll

❮ Previous
Next ❯

Citations

Feb 15, 2011·Hormones & Cancer·Brian L SpragueGale S Sisney
Mar 6, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rohit MehraRajal B Shah
Dec 2, 2006·Nature Clinical Practice. Oncology·Mark T FlemingHoward I Scher
Mar 11, 2008·Journal of Biopharmaceutical Statistics·Abel TilahunGeert Molenberghs
Jun 17, 2004·Journal of the National Cancer Institute·Arthur Schatzkin, Ulrike Peters
Sep 2, 2004·Journal of the National Cancer Institute·Ross L PrenticeElizabeth Yetley
Mar 23, 2011·Journal of the National Cancer Institute·Susan S Ellenberg
Jan 7, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Carrie R DanielMarch E Seabrook
Jan 29, 2009·Cancer Prevention Research·Arthur SchatzkinGeorge Davey-Smith
Sep 10, 2003·BMC Medical Research Methodology·Stuart G Baker, Barnett S Kramer
Dec 2, 2009·Environmental Health : a Global Access Science Source·Paolo VineisRoel Vermeulen
Nov 26, 2011·Breast Cancer Research : BCR·Norman F BoydSalomon Minkin
Jan 13, 2006·PLoS Medicine·Eduardo L Franco
Oct 1, 2007·Biomarkers in Medicine·Graeme A M Fraser, Ralph M Meyer
Sep 19, 2014·Genes & Nutrition·Vikki HoWill D King
Mar 29, 2003·Radiology·John J SmithJames H Thrall
Feb 7, 2013·Leukemia & Lymphoma·Frank Akwaa, Jane Liesveld
Jun 5, 2003·Expert Opinion on Therapeutic Targets·Barbara Fingleton
Feb 13, 2016·The Lancet Oncology·Lucinda BillinghamNeil Steven
Feb 17, 2015·Biometrical Journal. Biometrische Zeitschrift·Marc BuyseTomasz Burzykowski
May 1, 2012·Seminars in Oncology Nursing·Barbara K Dunn, Esther Akpa
Sep 8, 2010·Seminars in Oncology·Eva Szabo
Aug 28, 2009·Maturitas·Lisa J MartinNorman F Boyd
May 3, 2005·Obstetrics and Gynecology·David A Grimes, Kenneth F Schulz
Apr 1, 2008·Surgical Oncology Clinics of North America·Susan Tsai, Michael S Sabel
Feb 6, 2007·Bioorganic & Medicinal Chemistry·Rajeshwar P Verma, Corwin Hansch
Feb 14, 2007·Molecular Nutrition & Food Research·Young-In Kim
Sep 13, 2013·Pharmacoepidemiology and Drug Safety·Seoyoung C KimSebastian Schneeweiss
Feb 19, 2005·Critical Reviews in Oncology/hematology·Marie-France Demierre, Vernon K Sondak
Mar 27, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A WellerN M deSouza
Aug 7, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Milin R AcharyaAlex Sparreboom
Nov 19, 2005·Seminars in Oncology Nursing·Frank L Meyskens, Patricia Tully
Jun 9, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rachel Cooper, Johannes H A M Kaanders
Jul 16, 2014·Academic Radiology·Hidekazu YamamotoAshish Chandra
Oct 28, 2005·Statistics in Medicine·Christopher J Weir, Rosalind J Walley
Aug 23, 2005·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Martin Yaffe, Norman Boyd
Nov 3, 2005·Expert Opinion on Emerging Drugs·Paul J MulhollandEdward S Newlands
Jul 19, 2014·The British Journal of Ophthalmology·Felipe A Medeiros
Dec 6, 2014·American Journal of Respiratory and Critical Care Medicine·Gordon D Rubenfeld
Jul 18, 2009·Statistical Methods in Medical Research·Geert MolenberghsMarc Buyse
Sep 5, 2002·Nature Reviews. Cancer·Christopher Mark Overall, Carlos López-Otín
Apr 3, 2003·Nature Reviews. Cancer·Ruth EtzioniLeland Hartwell
Aug 24, 2004·Oncogene·Marjorie L McCullough, Edward L Giovannucci

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.